Analyst’s Top 4 Specialty Pharmaceutical Stocks to Buy Before Earnings
The analysts at Piper Jaffray are very positive on four top specialty pharmaceutical stocks with potential for a strong fourth-quarter rally in their shares.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 279Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales
Gilead Sciences reported disappointing third-quarter results after the market close on Monday.
What to Look For in Gilead Sciences Earnings Report
Gilead Sciences is set to report its third-quarter earnings after the U.S. markets close on Tuesday.
Amgen Posts 52-Week High, Beats It Again After Earnings
Amgen reported better-than-expected third-quarter 2014 results after markets closed Monday afternoon.
Pain Therapeutics and Durect Stung by Pfizer Move
Durect and Pain Therapeutics have been stung by Pfizer's decision to discontinue to develop Remoxy.
Sarepta Faces Major Hurdle, and Not From Ebola
Sarepta Therapeutics shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot.
Biotech Short Interest Becomes Stock Specific
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Merck Earnings Look Very Mixed in Major Restructuring
Merck reported better-than-expected third-quarter earnings Monday morning.
Lakeland Private Placement Comes at Severe Discount to Ebola Trade
Lakeland Industries announced that it entered into a definitive securities purchase agreement to raise $11.2 million in a private placement of common stock.
Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra
Pfizer's new buyback is simply too large and too significant to ignore, and it might jokingly be called "on Viagra."
New Ebola Fears in NYC Make Major Ebola Stock Waves (Updated)
ThinkstockJust when you thought the Ebola virus outbreak risk was dwindling down… Fresh headlines from Dow Jones and the New York post have put the markets on Ebola watch all over again. The location…
Will Celgene Become the Next $100 Billion Biotech Stock?
ThinkstockDoes Celgene Corporation (NASDAQ: CELG) have what it takes to make it to a $100 billion market cap? Some analysts would think so, following the favorable release of this biotech giant’s earnings. The company…
Companies That Benefit as Sexually Transmitted Disease Cases Keep Growing
The following companies were featured in a new Leerink report on understand testing trends for sexually transmitted diseases.
After Multiyear Turnaround, Is Boston Scientific Finally (and Really) Back?
24/7 Wall St. would ask if this turnaround in Boston Scientific earnings and outlook is really convincing investors.
3 Irish Specialty Pharmaceutical Stocks to Buy After Tax Inversion Implosion
A new research report from Merrill Lynch features three top pharmaceutical companies, dubbed the “Irish 3-Pack.”